Dr Lin Yee Chen (University of Minnesota Medical School, Minneapolis, MN, US) joins us to examine which artificial intelligence (AI) applications in heart failure are ready for clinical use today, and which remain experimental.
As AI moves from research settings into the clinic, separating genuine clinical utility from hype has become a pressing question for heart failure specialists.
In this interview, Dr Chen sets out where AI-enhanced electrocardiography (AI-ECG) is already informing screening and risk stratification, most notably in detecting asymptomatic left ventricular systolic dysfunction before symptoms develop, and in identifying patients at risk of atrial fibrillation, a major driver of heart failure. Dr Chen also addresses the validation any new tool must satisfy before clinicians can rely on it: generalisability across populations, calibration as well as discrimination, freedom from subgroup bias, and explainability to earn physician trust.
Interview Questions:
In 2026, where is ECG-based AI already changing heart failure screening or risk stratification?
Which AI-derived rhythm or atrial signals do you currently trust most for flagging heart failure risk?
For a new heart failure AI tool, what checks around population fit, calibration, bias, and interpretability must be in place before you rely on it?
In the next two to three years, which AI applications do you expect to enter routine heart failure care, and which will likely remain experimental?
For a busy heart failure clinic today, which one or two AI tools clearly add value without increasing workflow burden?
If every clinic could adopt one AI tool for heart failure, which would you choose, and what is the biggest risk of using it uncritically?
Editors: Jordan Rance
Videographer: TBC
Support: This is an independent interview produced by Radcliffe Cardiology.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
As AI moves from research settings into the clinic, separating genuine clinical utility from hype has become a pressing question for heart failure specialists.
In this interview, Dr Chen sets out where AI-enhanced electrocardiography (AI-ECG) is already informing screening and risk stratification, most notably in detecting asymptomatic left ventricular systolic dysfunction before symptoms develop, and in identifying patients at risk of atrial fibrillation, a major driver of heart failure. Dr Chen also addresses the validation any new tool must satisfy before clinicians can rely on it: generalisability across populations, calibration as well as discrimination, freedom from subgroup bias, and explainability to earn physician trust.
Interview Questions:
In 2026, where is ECG-based AI already changing heart failure screening or risk stratification?
Which AI-derived rhythm or atrial signals do you currently trust most for flagging heart failure risk?
For a new heart failure AI tool, what checks around population fit, calibration, bias, and interpretability must be in place before you rely on it?
In the next two to three years, which AI applications do you expect to enter routine heart failure care, and which will likely remain experimental?
For a busy heart failure clinic today, which one or two AI tools clearly add value without increasing workflow burden?
If every clinic could adopt one AI tool for heart failure, which would you choose, and what is the biggest risk of using it uncritically?
Editors: Jordan Rance
Videographer: TBC
Support: This is an independent interview produced by Radcliffe Cardiology.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
- Categoria
- Cardiology
- Tags
- radcliffe, cardiology, vascular
Commenta per primo questo video.









